Tomoiku Takaku

Oct 31, 2024 | acsjournals.onlinelibrary.wiley.com | Takeshi Kondo |Tomoiku Takaku |Naoki Watanabe |Eri Matsuki

INTRODUCTION The introduction of tyrosine kinase inhibitors (TKIs) has greatly improved the survival of patients with chronic myeloid leukemia (CML), aligning their life expectancy with that of the general population.1, 2 Many CML patients achieve and maintain a deep molecular response (DMR), making them potential candidates for treatment-free remission (TFR).3, 4 TFR is defined as maintaining a major molecular response (MMR) or DMR after stopping TKI therapy without needing to resume...